Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)

NCT02759601 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Tefinostat

Sponsor

Queen Mary University of London

Collaborators

[object Object]